Company

Zai Lab

再鼎医药

Zai Lab (再鼎医药) is a biopharmaceutical company dual-listed on NASDAQ (ZLAB) and the Hong Kong exchange (09688.HK), and a portfolio company of Qiming Venture Partners, whose weekly updates are elsewhere's main window into it. Recent coverage centers on its oncology push: its internally developed DLL3-targeting ADC zocilurtatug pelitecan (zoci, formerly ZL-1310) showed strong, durable responses in heavily pretreated extensive-stage small-cell lung cancer and moved from Phase 1 to a global registrational study in under two years — a trajectory that, per Amgen's and Boehringer Ingelheim's 2026 deal announcements, has made zoci the backbone of combination trials pairing it with their respective DLL3 T-cell engagers. It also stands up infrastructure to match that ambition — an oncology scientific advisory board formed in 2025, an in-house pipeline including an LRRC15 ADC and an IL-12 immunocytokine, and on the commercial side, an NMPA approval in early 2026 for Augtyro (repotrectinib) in NTRK-positive solid tumors, its second approved indication in China for that drug.

AI-generated — may contain errors, please verify.

Zai LabCompany
再鼎医药
渲染中…
Mentioned in 142 articles

Coverage